Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Fosun Pharmaceutical's...

    Fosun Pharmaceutical's non-binding proposal to buy Gland Pharma

    Written by savita thakur thakur Published On 2016-05-18T12:41:45+05:30  |  Updated On 18 May 2016 12:41 PM IST
    Fosun Pharmaceuticals non-binding proposal to buy Gland Pharma

    Hong Kong : Shanghai Fosun Pharmaceutical (Group) Co has made a non-binding proposal to buy India's Gland Pharma, which is backed by KKR and valued at up to $1.5 billion, to boost its drug manufacturing and research and development capacity.


    Shanghai Fosun's announcement on Monday of its interest in Gland Pharma is the first major move on a deal by the Fosun group of companies since Guo Guangchang, one of China's best-known entrepreneurs and the founder of flagship investment holding company Fosun International, briefly went missing late last year.


    The move is also a departure from the group's strategy of largely targeting companies in developed markets and comes after sources said last week that Fosun International was among suitors bidding for ACR Capital Holdings, the owner of Singapore's biggest reinsurance firm.


    Gland Pharma founders and KKR, who jointly own about 96 percent of the Hyderabad-based injectable drugs manufacturer, are selling their combined stake, valued at between $1 billion and $1.5 billion, people with direct knowledge of the matter told Reuters in April.


    Global buyout firm Advent International and U.S.-based Baxter International are also among suitors preparing to submit separate bids to buy Gland Pharma, the people had said. Advent, Baxter and KKR had declined to comment.


    Shanghai Fosun said the proposal was made through its unit Fosun Industrial Co Ltd. The company gave no further details.


    Shanghai Fosun shares closed up 0.9 percent on Monday, in line with a 0.7 percent rise in the benchmark Shanghai share index. The company has a market value of about $6.5 billion.


    DRIVING FORCE
    Billionaire Guo has been the key driving force behind the group's M&A push and his disappearance had raised concerns about Fosun and its group companies' ability to pursue outbound deals. He returned to work after assisting authorities with an investigation.


    Fosun has slowed down on acquisitions after spending about $30 billion in outbound M&A over the past two decades, largely acquiring insurance companies and other real estate assets mainly in Europe and the United States.


    In recent months, Fosun has scrapped bids for Israeli insurer Phoenix Holdings Ltd and Anglo-German banking group BHF Kleinwort Benson Group and is more focused on bringing its debt under control.


    But Guo, a self-styled disciple of Warren Buffett, told Bloomberg this month the company will actively look for investments in countries including Brazil, Russia, India and China as there are fewer investment opportunities in Europe and the United States as the overall valuations have come expensive.

    AdventBaxterGland PharmaGuo GuangchangKKRShanghai Fosun Pharmaceutical Co
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok